Therefore, Topo IIα levels are elevated not only in osimertinib-resistant EGFRm NSCLC cell lines but also in EGFRm NSCLC tissues relapsed from EGFR-TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.